Circio: Partnerships and Licensing

Partnership and licensing opportunities from Circio.

 

Partnership Title: Building next generation RNA therapeutics-circular RNA

Strategic focus areas

Circio´s main areas of focus are circular RNA therapeutics and immunotherapy in oncology and vaccines, with plans to expand into rare disease and cell therapy.

circular RNA – circVec platform

• circVec is our unique, proprietary technology for in situ circRNA production, which enables enhanced and durable expression of proteins compared to conventional vectors.
• Circio is exploring the potential of circVec in various therapeutic areas and plans to develop circRNA candidates both in-house and through partnerships with pharmaceutical companies.

We are seeking partnerhips with companies that have:

• experience in rare disease, protein replacement and gene therapy who are interested in exploring the potential of long term high level protein expression to treat patients with monogenetic disorders.
• vector or drug delivery technology which enables durable and tissue specific delivery of DNA and RNA therapeutics.
• engineered or proprietary proteins or peptides suitable for vector delivery to solid tumors or other specific tissues/diseases.

• Licencing Out
  We offer our products to other companies on an 'out-licensing' basis.

• Research and Development
  We offer co-development opportunities.

• Biopharmaceuticals
  - Biopharmaceuticals-Discovery Platforms
  - Biopharmaceuticals-Technology

• Antineoplastic and Immunomodulating Agents
  - Immuno-oncology
  - Immuno-stimulants

• Anti-infectives for systemic use
  - Vaccines

Claim This Profile

This is the Partnership and Licensing section of the company profile page for Circio on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.